CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma...
Phase 1
Cleveland, Ohio, United States and 8 other locations
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...
Phase 3
Cleveland, Ohio, United States and 135 other locations
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Cleveland, Ohio, United States and 212 other locations
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are:...
Phase 1
Cleveland, Ohio, United States and 19 other locations
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitiza...
Phase 2
Cleveland, Ohio, United States and 68 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Cleveland, Ohio, United States and 221 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Cleveland, Ohio, United States and 33 other locations
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It...
Phase 2
Cleveland, Ohio, United States and 27 other locations
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy...
Phase 1
Cleveland, Ohio, United States and 42 other locations
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safet...
Phase 1
Cleveland, Ohio, United States and 7 other locations
Clinical trials
Research sites
Resources
Legal